Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

My weight concerns mainly injure my considerable vanity, and I’m not about to outsource my self-esteem issue to Big Pharma if ...

The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single ...

Tablet forms of semaglutide — better known as Ozempic, an injectable drug for weight-loss — are already in trials for Alzheimer’s and results are expected in late 2025. Mr Cummings ...

Independence Blue Cross has instituted an 18-month benefit exclusion on certain drugs that receive accelerated approval from ...

Stay updated on the latest potential FDA drug approvals in 2025, including an expanded label for Ozempic and new, nonopioid painkillers.

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

Ozempic, Wegovy and Mounjaro may offer serious health benefits beyond weight loss. The GLP-1 medications have been linked to decreased risks of heart disease, kidney disease and Alzheimer’s ...